Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: A randomized placebo-controlled trial - Fadini, G P; Bonora, B M; Zatti, G (Cardiovasc Diabetol, 2017)
et al.